Multiple Myeloma Immunophenotype Related to Chromosomal Abnormalities Used in Risk Assessment

Radzevičius, Mantas; Dirsė, Vaidas; Klimienė, Indrė; Matuzevičienė, Rėda; Kučinskienė, Zita Aušrelė; Pečeliūnas, Valdas

doi:10.3390/diagnostics12092049

Open AccessArticle

Multiple Myeloma Immunophenotype Related to Chromosomal Abnormalities Used in Risk Assessment

by

Mantas Radzevičius

^1,*

,

Vaidas Dirsė

²,

Indrė Klimienė

²,

Rėda Matuzevičienė

^1,3

,

Zita Aušrelė Kučinskienė

¹ and

Valdas Pečeliūnas

^2,4

¹

Department of Physiology, Biochemistry, Microbiology and Laboratory Medicine, Institute of Biomedical Sciences, Faculty of Medicine, Vilnius University, 03101 Vilnius, Lithuania

²

Hematology, Oncology and Transfusion Medicine Center, Vilnius University Hospital Santaros Klinikos, 08661 Vilnius, Lithuania

³

Center of Laboratory Medicine, Vilnius University Hospital Santaros Klinikos, 08661 Vilnius, Lithuania

⁴

Clinic of Internal Diseases, Family Medicine and Oncology, Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, 03101 Vilnius, Lithuania

^*

Author to whom correspondence should be addressed.

Diagnostics 2022, 12(9), 2049; https://doi.org/10.3390/diagnostics12092049

Submission received: 10 July 2022 / Revised: 2 August 2022 / Accepted: 22 August 2022 / Published: 24 August 2022

(This article belongs to the Special Issue Innovations in Laboratory Hematology and Flow Cytometry)

Download

Browse Figures

Versions Notes

Abstract

(1) Background: At diagnosis, multiplemyeloma risk estimation includes disease burden, end-organ damage, and biomarkers, with increasing emphasis on genetic abnormalities. Multicolor flow cytometry (MFC) is not always considered in risk estimation. We demonstrate associations found between genetic abnormalities and antigen expression of plasma cells measured by MFC. (2) Methods: Single nucleotide polymorphism microarray (SNP-A) karyotyping as well as MFC using standardized next-generation flow (NGF) panels and instrument settings were performed from bone marrow aspirates at the time of diagnosis. (3) Results: We uncovered specific immunophenotype features related to different genetic risk factors. Specifically, we found higher malignant/normal plasma cell ratio and lower expression of CD27, CD38, CD45, CD56, CD117 and CD138 in higher-risk genetic groups or risk categories.

Keywords: flow cytometry; single nucleotide polymorphism microarray; multiple myeloma; immunophenotype; risk assessment

Share and Cite

MDPI and ACS Style

Radzevičius, M.; Dirsė, V.; Klimienė, I.; Matuzevičienė, R.; Kučinskienė, Z.A.; Pečeliūnas, V. Multiple Myeloma Immunophenotype Related to Chromosomal Abnormalities Used in Risk Assessment. Diagnostics 2022, 12, 2049. https://doi.org/10.3390/diagnostics12092049

AMA Style

Radzevičius M, Dirsė V, Klimienė I, Matuzevičienė R, Kučinskienė ZA, Pečeliūnas V. Multiple Myeloma Immunophenotype Related to Chromosomal Abnormalities Used in Risk Assessment. Diagnostics. 2022; 12(9):2049. https://doi.org/10.3390/diagnostics12092049

Chicago/Turabian Style

Radzevičius, Mantas, Vaidas Dirsė, Indrė Klimienė, Rėda Matuzevičienė, Zita Aušrelė Kučinskienė, and Valdas Pečeliūnas. 2022. "Multiple Myeloma Immunophenotype Related to Chromosomal Abnormalities Used in Risk Assessment" Diagnostics 12, no. 9: 2049. https://doi.org/10.3390/diagnostics12092049

APA Style

Radzevičius, M., Dirsė, V., Klimienė, I., Matuzevičienė, R., Kučinskienė, Z. A., & Pečeliūnas, V. (2022). Multiple Myeloma Immunophenotype Related to Chromosomal Abnormalities Used in Risk Assessment. Diagnostics, 12(9), 2049. https://doi.org/10.3390/diagnostics12092049

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Menu

Multiple Myeloma Immunophenotype Related to Chromosomal Abnormalities Used in Risk Assessment

Abstract

Share and Cite

Article Metrics

Article Access Statistics

Further Information

Guidelines

MDPI Initiatives

Follow MDPI